Advertisement

Topics

RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer

07:00 EDT 17 Apr 2018 | Cancer Networks

A biomarker known as RAD51 was found to be correlated with resistance to PARP inhibitor treatment in a study of breast cancer that harbors BRCA mutations.

Original Article: RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...